1. Home
  2. WAFD vs IBRX Comparison

WAFD vs IBRX Comparison

Compare WAFD & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WaFd Inc.

WAFD

WaFd Inc.

HOLD

Current Price

$32.05

Market Cap

2.5B

Sector

Finance

ML Signal

HOLD

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$1.98

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WAFD
IBRX
Founded
1917
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
WAFD
IBRX
Price
$32.05
$1.98
Analyst Decision
Hold
Strong Buy
Analyst Count
5
7
Target Price
$31.40
$9.71
AVG Volume (30 Days)
566.6K
13.6M
Earning Date
01-15-2026
11-04-2025
Dividend Yield
3.37%
N/A
EPS Growth
5.31
N/A
EPS
2.63
N/A
Revenue
$717,732,000.00
$82,555,000.00
Revenue This Year
$8.66
$667.18
Revenue Next Year
$4.77
$93.03
P/E Ratio
$12.18
N/A
Revenue Growth
1.95
1025.95
52 Week Low
$23.75
$1.83
52 Week High
$33.81
$4.27

Technical Indicators

Market Signals
Indicator
WAFD
IBRX
Relative Strength Index (RSI) 44.91 40.59
Support Level $32.99 $2.07
Resistance Level $33.25 $2.29
Average True Range (ATR) 0.59 0.13
MACD -0.19 -0.02
Stochastic Oscillator 1.63 5.44

Price Performance

Historical Comparison
WAFD
IBRX

About WAFD WaFd Inc.

WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: